This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Google Scholar
Right arrow Articles by Segura-Velázquez, R.
Right arrow Articles by Sarukhan, A.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Segura-Velázquez, R.
Right arrow Articles by Sarukhan, A.

 Previous Article  |  Next Article 

Clinical and Vaccine Immunology, September 2009, p. 1338-1343, Vol. 16, No. 9
1071-412X/09/$08.00+0     doi:10.1128/CVI.00106-09
Copyright © 2009, American Society for Microbiology. All Rights Reserved.

Towards Identification of the Mechanisms of Action of Parasite-Derived Peptide GK1 on the Immunogenicity of an Influenza Vaccine{triangledown}

René Segura-Velázquez,1,2 Gladis Fragoso,1 Edda Sciutto,1 and Adelaida Sarukhan1*

Instituto de Investigaciones Biomédicas,1 Facultad de Ciencias, Universidad Nacional Autónoma de México, México City, DF, México2

Received 9 March 2009/ Returned for modification 19 June 2009/ Accepted 11 July 2009

Previous studies have shown that the synthetic peptide GK1, derived from Taenia crassiceps cysticerci, enhances the immunogenicity of the commercial inactivated influenza vaccine Fluzone in both young and aged mice. In particular, antibody responses were much improved. Since GK1 is a peptide and is rapidly cleared from the body, it offers the possibility to improve vaccine performance without undesirable effects. This study was therefore designed to understand the mechanisms of action involved in the adjuvant properties of GK1. For this, transgenic mice expressing a T-cell receptor specific for an epitope from the influenza virus hemagglutinin (HA) protein were employed. The GK1 peptide significantly increased the in vivo proliferative response of HA-specific CD4+ T cells when it was coimmunized with the HA epitope. Dendritic cells treated in vitro with GK1 were capable of enhancing T-cell activation. Furthermore, in synergy with lipopolysaccharide, GK1 enhanced the expression of major histocompatibility complex class II and costimulatory molecules of dendritic cells and promoted the secretion of proinflammatory cytokines and chemokines upon antigen-driven T-cell interaction. These data provide important insights into the mechanism that underlies the GK1 adjuvant capacity observed previously and underline the feasibility of using the transgenic mouse model described herein as a tool for investigation of the modes of action of different influenza vaccine adjuvants.

* Corresponding author. Present address: Istituto Clinico Humanitas, Rozzano, Milan, Italy. Phone: 39 0282245113. Fax: 39 0282245101. E-mail: adelaida.sarukhan{at}humanitas.it

{triangledown} Published ahead of print on 15 July 2009.

Clinical and Vaccine Immunology, September 2009, p. 1338-1343, Vol. 16, No. 9
1071-412X/09/$08.00+0     doi:10.1128/CVI.00106-09
Copyright © 2009, American Society for Microbiology. All Rights Reserved.





Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»